Organon Reboots with Biotech

Organon's biologics R&D push relects similar moves by other mid-sized firms, and could help the company recover after a series of setbacks. But building biotech from discovery upwards will take time.

By Christopher Morrison

That firms across the pharmaceutical spectrum continue to wade into biotech R&D underscores the importance of combining large- and small-molecule...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from In Vivo Archive

More from In Vivo